Data from the first cost-effectiveness analysis for the U.S. covering the lifetime costs and effectiveness of the OPRA™ Implant System for transfemoral use in amputees versus a socket prosthesis was presented at the 99th Annual American Congress of Rehabilitation Medicine (ACRM) conference.
The analyses covered various health states that a patient may be in over a typical 42-year life span, wearing a socket prosthesis, or having an OPRA™ Implant System. The initial study concluded that for active transfemoral amputees, the use of the OPRA™ Implant System is a cost-effective alternative to a socket prosthesis. Data showed that the use of the OPRA™ Implant System is well within accepted threshold values of U.S. cost-effectiveness therapies.
Tom Dugan, president of Integrum US, stated, “We are pleased to build upon this definitive evidence that the OPRA™ Implant System should be considered a reasonable alternative for socket prosthesis patients who are physically active transfemoral amputees. We look forward to sharing these findings with our customers and payers.”
Read more about the study in the press release from Integrum.